Short answer
ImmunityBio, Inc. (IBRX) filed an 8-K current report with the SEC on November 9, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). ANKTIVA plus BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 trial.
ImmunityBio, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- ANKTIVA plus BCG met the primary endpoint in Cohort A of the randomized QUILT-2.005 trial
- Result applies to BCG-naïve, non-muscle invasive bladder cancer patients
- Positive trial outcome supports ANKTIVA’s potential expansion into earlier-line bladder cancer treatment
- Press release contains endpoint results and supporting data in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- QUILT-2.005 met its primary efficacy endpoint in 370 BCG-naïve, high-grade NMIBC patients versus BCG alone
- Statistically significant efficacy improvement supports potential frontline expansion beyond ANKTIVA’s current BCG-unresponsive indication
- Safety resembled BCG alone, with no treatment-related deaths and maintained patient-reported quality of life
- Median response duration was not reached, supporting potential durability but requiring longer follow-up
- sBLA submission remains targeted for year-end 2026, creating a regulatory catalyst and possible addressable-market expansion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ImmunityBio, Inc. 8-K filings
Get the next IBRX 8-K as it lands
Follow IBRX for push alerts, or ask the research agent what this filing means.